NL-OMON53175尚未招募不适用
Doetinchem Cohort Study round 8 - DCS8
RIVM0 个研究点目标入组 5,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Participants who have participated in earlier rounds of the Doetinchem Cohort
- •Study, and a new random sample of participants (men and women), drawn from the
- •register of inhabitants of Doetinchem, men and women aged 40-60 years of age to
- •replenisch the cohort again with younger age groups.
排除标准
- •Not being able to participate due to physical or mental reasons (judgement of
- •the respondent), active withdrawal
研究者
相似试验
招募中
不适用
Doetinchem Cohort Study round 7diverse chronische aandoeningen, kwaliteit van leven, etcchronic diseasesNL-OMON46608RIVM4,500
已完成
不适用
Continuation of the Doetinchem Cohort Studycommon diseases100822061001842410038716NL-OMON38394RIVM4,500
进行中（未招募）
1 期
Study Brand Name : REPAROStudy full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the safety and efficacy of two doses (10 µg/ml and 20 µg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with Stage 2 and 3 of neurotrophic keratitisAdult patients diagnosed with unilateral stage 2 (persistent epithelial defect) and stage 3 (corneal ulcer) NK refractory to one or more conventional non-surgical treatments. Patients with Controlateral eye affected with stage 1 NK can be enrolled.MedDRA version: 17.1Level: LLTClassification code 10032064Term: Other forms of keratitisSystem Organ Class: 100000004853EUCTR2012-002527-15-PLDompé farmaceutici s.p.a174
进行中（未招募）
1 期
Study Brand Name : REPAROStudy full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the safety and efficacy of two doses (10 µg/ml and 20 µg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with Stage 2 and 3 of neurotrophic keratitisAdult patients diagnosed with unilateral stage 2 (persistent epithelial defect) and stage 3 (corneal ulcer) NK refractory to one or more conventional non-surgical treatments. Patients with Controlateral eye affected with stage 1 NK can be enrolled.MedDRA version: 16.1Level: LLTClassification code 10032064Term: Other forms of keratitisSystem Organ Class: 100000004853EUCTR2012-002527-15-HUDompé s.p.a174
进行中（未招募）
1 期
Study Brand Name : REPAROStudy full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the safety and efficacy of two doses (10 µg/ml and 20 µg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with Stage 2 and 3 of neurotrophic keratitisAdult patients diagnosed with unilateral stage 2 (persistent epithelial defect) and stage 3 (corneal ulcer) NK refractory to one or more conventional non-surgical treatments. Patients with Controlateral eye affected with stage 1 NK can be enrolled.MedDRA version: 16.1Level: LLTClassification code 10032064Term: Other forms of keratitisSystem Organ Class: 100000004853EUCTR2012-002527-15-BEDompé s.p.a174